Horizon pads gout pipeline with deal for Arrowhead’s siRNA therapy

Months after broadening its pipeline via the $3 billion-plus takeout of Viela, Horizon is adding to its gout franchise through a smaller deal with Arrowhead for a preclinical siRNA therapeutic.

Horizon Therapeutics plc (NASDAQ:HZNP) will pay $40 million up front for global rights to siRNA therapeutic ARO-XDH, adding to a gout portfolio led by its marketed drug Krystexxa pegloticase. With $405.9 million in 2020 sales, Krystexxa was Horizon’s second-biggest seller after Tepezza teprotumumab-trbw, a treatment for thyroid eye disease that brought in $820 million...